Cargando…
Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157146/ https://www.ncbi.nlm.nih.gov/pubmed/34069240 http://dx.doi.org/10.3390/jcm10102131 |
_version_ | 1783699615876382720 |
---|---|
author | Molla, Meritxell Fernandez-Plana, Julen Albiol, Santiago Fondevila, Constantino Vollmer, Ivan Cases, Carla Garcia-Criado, Angeles Capdevila, Jaume Conill, Carles Fundora, Yliam Fernandez-Martos, Carlos Pineda, Estela |
author_facet | Molla, Meritxell Fernandez-Plana, Julen Albiol, Santiago Fondevila, Constantino Vollmer, Ivan Cases, Carla Garcia-Criado, Angeles Capdevila, Jaume Conill, Carles Fundora, Yliam Fernandez-Martos, Carlos Pineda, Estela |
author_sort | Molla, Meritxell |
collection | PubMed |
description | The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments. |
format | Online Article Text |
id | pubmed-8157146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81571462021-05-28 Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT Molla, Meritxell Fernandez-Plana, Julen Albiol, Santiago Fondevila, Constantino Vollmer, Ivan Cases, Carla Garcia-Criado, Angeles Capdevila, Jaume Conill, Carles Fundora, Yliam Fernandez-Martos, Carlos Pineda, Estela J Clin Med Review The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments. MDPI 2021-05-14 /pmc/articles/PMC8157146/ /pubmed/34069240 http://dx.doi.org/10.3390/jcm10102131 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Molla, Meritxell Fernandez-Plana, Julen Albiol, Santiago Fondevila, Constantino Vollmer, Ivan Cases, Carla Garcia-Criado, Angeles Capdevila, Jaume Conill, Carles Fundora, Yliam Fernandez-Martos, Carlos Pineda, Estela Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title | Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title_full | Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title_fullStr | Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title_full_unstemmed | Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title_short | Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT |
title_sort | limited liver or lung colorectal cancer metastases. systemic treatment, surgery, ablation or sbrt |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157146/ https://www.ncbi.nlm.nih.gov/pubmed/34069240 http://dx.doi.org/10.3390/jcm10102131 |
work_keys_str_mv | AT mollameritxell limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT fernandezplanajulen limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT albiolsantiago limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT fondevilaconstantino limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT vollmerivan limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT casescarla limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT garciacriadoangeles limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT capdevilajaume limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT conillcarles limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT fundorayliam limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT fernandezmartoscarlos limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt AT pinedaestela limitedliverorlungcolorectalcancermetastasessystemictreatmentsurgeryablationorsbrt |